Ratings Voxel S.A.

Equities

VOX

PLVOXEL00014

Delayed Warsaw S.E. Other stock markets 07:47:46 13/05/2024 pm IST			5-day change	1st Jan Change
92.8 ^PLN	-0.43%		-0.22%	+18.07%

11/03	Amadeus IT Group Buys Voxel Media in EUR113 Million Deal	MT
2023	Voxel S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Sales forecast by analysts have been recently revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	ESG Refinitiv
VOXEL S.A.	+18.07%	25Cr	-
SONIC HEALTHCARE LIMITED	-15.77%	848.84Cr	B+
RADNET, INC.	+57.28%	408.19Cr	C+
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.78%	242.38Cr	B-
SYNLAB AG	-9.81%	242.38Cr	-
DR. LAL PATHLABS LIMITED	-3.24%	233.43Cr	B-
NEOGENOMICS, INC.	-1.92%	201.4Cr	C-
FLEURY S.A.	-20.07%	152.85Cr	A-
DIAN DIAGNOSTICS GROUP CO.,LTD.	-38.30%	125.94Cr	C+
METROPOLIS HEALTHCARE LIMITED	+2.19%	107.19Cr	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes